Longeveron(US:LGVN) globenewswire.com·2024-05-28 12:05Core Viewpoint - Longeveron Inc. is actively participating in the BIO International Convention to explore strategic partnerships for its Alzheimer's disease program, which has shown promising results in clinical trials [1][2]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with its lead product being Lomecel-B™, an allogeneic cellular therapy derived from the bone marrow of young, healthy adult donors [5]. - The company is pursuing three main pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [5]. Clinical Development - Lomecel-B™ has demonstrated the ability to slow or prevent disease worsening in patients with mild Alzheimer's disease during the completed Phase 2a clinical trial (CLEAR MIND), achieving primary safety and secondary efficacy endpoints [3]. - Statistically significant improvements were observed in pre-specified clinical and biomarker endpoints for specific groups treated with Lomecel-B™ compared to placebo [3]. - The full results from the CLEAR MIND study will be presented at the 2024 Alzheimer's Association International Conference (AAIC) [3]. Recent Announcements - Longeveron announced top-line results for the CLEAR MIND Phase 2a clinical trial on October 5, 2023, and provided additional clinical data on December 20, 2023 [4].